Kardigan, Inc.
KARD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KARD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KARD
Kardigan, Inc. is a clinical-stage precision therapeutics company developing targeted treatments for specific cardiovascular diseases with no approved therapies, including three late-stage programs: Danicamtiv for genetic dilated cardiomyopathy, Ataciguat for calcific aortic valve stenosis, and Tonlamarsen for acute severe hypertension.
Key risk: No revenue or approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials · 2 catalysts for Kardigan, Inc..
Kardigan, Inc. is a clinical-stage precision therapeutics company developing targeted treatments for specific cardiovascular diseases with no approved therapies, including three late-stage programs: Danicamtiv for genetic dilated cardiomyopathy, Ataciguat for calcific aortic valve stenosis, and Tonlamarsen for acute severe hypertension.
- Kardigan is a clinical-stage precision therapeutics company focused on cardiovascular diseases with no approved treatments [sec_mda · as of 2026-08-11].
- The company has three late-stage programs: Danicamtiv (genetic DCM), Ataciguat (moderate CAVS), and Tonlamarsen (post-hospitalization ASH) [sec_mda · as of 2026-08-11].
- As of June 30, 2026, Kardigan had cash, cash equivalents, and investments of $660.7 million and an accumulated deficit of $453.4 million [sec_mda · as of 2026-08-11].
- The company completed its IPO on June 22, 2026, issuing 28,750,000 shares of common stock [sec_mda · as of 2026-08-11].
- Kardigan has not yet generated any revenue and has incurred significant operating losses, with net losses of $172.3 million for the six months ended June 30, 2026 [sec_mda · as of 2026-08-11].
What works
- Kardigan targets well-defined patient populations with no approved therapies, potentially creating new standards of care [sec_mda · as of 2026-08-11].
- The company has a management team with experience from MyoKardia, indicating relevant expertise in cardiovascular drug development [sec_mda · as of 2026-08-11].
- As of June 30, 2026, Kardigan had $660.7 million in cash, cash equivalents, and investments, providing a runway of at least twelve months [sec_mda · as of 2026-08-11].
What to weigh
- Kardigan has not yet generated any revenue or demonstrated an ability to obtain regulatory approvals or commercialize products [sec · filed 2026-05-26].
- The company has a history of significant operating losses, with an accumulated deficit of $453.4 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Kardigan will need to raise substantial additional capital to fund its operations and clinical trials, and its future capital requirements are uncertain [sec_mda · as of 2026-08-11].
- The company's business is highly dependent on the success of its three late-stage product candidates, any of which could fail in clinical trials [sec · filed 2026-05-26].
From the filings
Quoted directly from source documents.
Kardigan is a clinical-stage precision therapeutics company developing medicines for cardiovascular diseases with no approved treatments.
“a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.”
SEC MD&A · August 11, 2026
The company has three late-stage programs: Danicamtiv, Ataciguat, and Tonlamarsen.
“Our three late-stage programs include Danicamtiv, which we are developing for the treatment of genetic dilated cardiomyopathy ("DCM"), Ataciguat, which is aimed at slowing the progression of calcific aortic valve stenosis ("CAVS") in patients with moderate disease, and Tonlamarsen, which we are developing for the management of blood pressure ("BP") in acute severe hypertension ("ASH") post-hospitalization.”
SEC MD&A · August 11, 2026
As of June 30, 2026, Kardigan had $660.7 million in cash, cash equivalents, and investments.
“As of June 30, 2026, we had cash, cash equivalents and investments of $660.7 million.”
SEC MD&A · August 11, 2026
Kardigan has incurred significant operating losses and an accumulated deficit.
“As of June 30, 2026, we had an accumulated deficit of $453.4 million.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2028-01-01 · Phase3_Topline — Topline results from a Phase 2b/3 adaptive, randomized, double-blind, placebo-controlled study of Danicamtiv in genetic DCM.
- 2033-01-01 · Phase3_Topline — Topline results from an open-label extension study assessing long-term safety and efficacy of Danicamtiv in adults.
Risks & what to watch (4)›
Key risks
- No revenue or approved products — Kardigan has not generated any revenue or obtained regulatory approval for any product candidate [sec · filed 2026-05-26].
- Dependence on late-stage pipeline — The company's success depends heavily on Danicamtiv, Ataciguat, and Tonlamarsen, any of which may fail [sec · filed 2026-05-26].
- Need for additional capital — Kardigan will need to raise substantial additional capital to fund operations and clinical trials [sec_mda · as of 2026-08-11].
- Significant operating losses — The company has an accumulated deficit of $453.4 million and net losses of $172.3 million in H1 2026 [sec_mda · as of 2026-08-11].
What to watch
- Phase 3 topline data for Danicamtiv in genetic DCM, expected around 2028-01-01 [upcoming catalysts].
- Phase 3 topline data for Danicamtiv long-term safety and efficacy, expected around 2033-01-01 [upcoming catalysts].
- Progress and enrollment updates for Ataciguat and Tonlamarsen clinical trials [sec_mda · as of 2026-08-11].
- Cash burn rate and any future financing activities, given the need for additional capital [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Kardigan, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kardigan, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
14.9 months
D/E 0.17 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~489d
3 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Kardigan, Inc.?
Kardigan, Inc. is a clinical-stage precision therapeutics company developing targeted treatments for specific cardiovascular diseases with no approved therapies, including three late-stage programs: Danicamtiv for genetic dilated cardiomyopathy, Ataciguat for calcific aortic valve stenosis, and Tonlamarsen for acute severe hypertension.
What is Kardigan, Inc.'s next catalyst?
Kardigan, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess th" — expected January 1, 2028.
Who is the CEO of Kardigan, Inc.?
Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA is the chief executive officer of Kardigan, Inc. (KARD).
Where is Kardigan, Inc. headquartered?
Kardigan, Inc. (KARD) is headquartered in Princeton, NJ, United States.
What therapeutic areas does Kardigan, Inc. focus on?
Kardigan, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.